Monitor ASCO 2026 presentations (May 29–June 2) for detailed efficacy/safety data on pumitamig and gotistobart. Positive data could drive near-term upside for BNTX, but no regulatory or commercial milestones are imminent. Watch for analyst reactions and potential partnership updates.
Price Chart
Executive Summary
BioNTech announced new clinical data for pumitamig (Phase 2/3 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRESERVE-004 in platinum-resistant ovarian cancer) to be presented at ASCO 2026. The data show encouraging anti-tumor activity and durable overall survival, supporting the company's late-stage oncology pipeline of 25+ Phase 2/3 trials including 13 pivotal studies. No financial figures, guidance, or regulatory decisions were disclosed.
Key Facts
- Pumitamig (PD-L1 × VEGF-A bispecific) interim Phase 2 data from ROSETTA Lung-02 in 1L NSCLC shows encouraging anti-tumor activity across PD-L1 levels; third global dataset to show consistent activity.
- Gotistobart (anti-CTLA-4) Phase 2 PRESERVE-004 data in platinum-resistant ovarian cancer shows durable anti-tumor activity and clinically meaningful overall survival.
- BioNTech has 25+ Phase 2/3 trials, including 13 ongoing pivotal trials and novel-novel combination trials with ADCs.
- No revenue, EPS, guidance, or financial data were provided in the press release.
- Presentations at ASCO 2026 (May 29–June 2) include two oral presentations and four trial-in-progress posters.
Financial Impact
No financial figures disclosed; pipeline updates are non-financial catalysts.
Risk Factors
- Clinical data at ASCO may not meet expectations, leading to stock volatility.
- No financial guidance or revenue catalysts provided; pipeline remains early-stage with execution risk.
- Competition in NSCLC and ovarian cancer from established PD-1/CTLA-4 therapies and ADCs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299948 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.90 (−1.98%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.90 (−1.98%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.90 (+5.07%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.90 (−12.62%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.90 (+4.42%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.90 (−6.08%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.90 (+5.04%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.90 (+5.04%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.90 (+4.36%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.90 (+13.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access